An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)

Inclusion Criteria

• •Males or females aged more than18
• •HBsAg-positive DLBCL patients (it is possible to enrol the patients with combined DLBCL and low grade lymphoma such as follicular lymphoma)
• •Previously untreated DLBCL patients who are suitable for receiving R-CHOP chemotherapy
• •Serum ALT no more than 2 x ULN (including normal ALT)
• •Life expectancy 6 months
• •A negative serum or urine pregnancy test prior to treatment must be available both for pre menopausal women and for women who are no more than 1 years after the onset of menopause.
• •Informed consent